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TREATMENT OF BLADDER CANCER 

ANTHONY BUSUITIL 
INTRODUCTION 
The urothelium or transitional 
epithelium lines the entire urinary 
tract from the renal pelvi-calyceal 
systems as far down as the larger 
part of the urethra, and £he 
pathological changes which can be 
observed in it are essentially 
identical irrespective of the actual 
anatomical location. On light 
microscopy the urothelium in the 
bladder comprises 4 to 7 layers of 
cells, depending on its degree of 
distension. The layer which is 
adjacent to the basal lamina consists 
of mitotically active, 'reserve' 
epithelial cells and the next few 
layers are made up 0 polygonal cells 
with central nuclei, and they exhibit 
an orientation parallel to the 
basement membrane. The 
uppermost layer consists of larger 
cells which are often multinucleated 
and cover several of the underlying 
epithelial cells and are therefore 
known as 'umbrella' cells. 
Over the last two decades, the 
incidence of urothelial carcinoma of 
the bladder has gradually increased 
on a worldwide basis with only minor 
ethnic variations, as for example a 
slightly decreased incidence among 
the black population of the United 
States. Perhaps this may be 
reflecting the trend towards 
increasing urbanisation and 
industrialisation with a consequent 
increase in smoking, in atmospheric 
pollution and exposure to possible 
carcinogenic agents which enter the 
body and are excreted in the urine. 
The urinary bladder is the site where 
there is maximal and most prolonged 
urothelial contact with urine and it 
is the area which is demonstrating 
this increase in neoplastic lesions. 
Surgical resection of tumours 
through a cystoscope and diathermy 
are still the mainstays of the 
treatment of bladder cancers but 
once there is infiltration of the other 
layers of the bladder there is a 
tendency for spread to occur outwith 
the bladder. When spread has 
occurred, various treatment 
modalities have been used in 
controlling such tumours, and these 
have ranged from the instillation 
locally of chemotherapeutic agents, 
to systemic courses of single and 
multi-agent chemotherapy, to 
radiotherapy and even to local 
hyperthermia The rationale for all 
these forms of treatment is a 
strenuous attempt to spare the 
patient a cystectomy with all its 
inherent inconveniences, side­
effects and biochemical 
derangements. 
An essential aspect of the treatment 
of bladder carcinomas is careful 
planning and tailor-making of the 
treatment to the needs of each 
individual patient (1). This can only 
be achieved if there has been an 
adequate and comprehensive 
assessment of the degree of 
differentiation and spread of each 
tumour through a joint clinco­
pathological assessment. An 
integral part of such an assessment 
is the thorough examination of the 
other ' normaT' areas of the bladder 
which are not obviously involved by 
tumour (1;2;3). Each quadrant of 
the bladder needs to be biopsied on 
the same occasion that the tumour 
is resected. These biopsies may show 
premalignant, hyperplastic or 
atypical changes indicating that the 
urothelium elsewhere in the bladder 
is also involved in a ' field change ' of 
carcinogenesis and is unstable, being 
a potential source of further trouble 
to the patient. The importance of 
this phenomenon was originally 
brought home through the ' mapping 
, studies on cystectomy specimens 
which were carried out by Koss first 
in Newcastle and later in the States 
(4,5). 
UROTHELIAL CARCINOMA 
. in SITU 
In some of these dysplastic bladders 
the changes amount to intra­
epithelial carcinoma or carcinoma 
in situ. This change was defined in 
the WHO manual as a 1esion in 
which there is definite anaplasia of 
the surface epithelium without the 
formation of papillary structures 
and without infiltration'. In this 
context anaplasia refers to both a 
cytological change and also to an 
architectural aEnormality with a 
disturbance in the polarity or 
orientation of the epithelial cells 
(6). Such superficially 
carcinomatous urothelial linings are 
usually frayed and irregular due to 
a loss of cohesion between the 
epithelial cells, and portions of them 
are detached free and are passed 
out with the urine. They can 
therefore be picked up on cytological 
screening, and this method is of 
great value in the diagnosis and 
follow-up of such patients. 
Furthermore some patients exhibit 
the changes of carcinoma in situ in 
the absence of any other tumour in 
their bladders (7,8). Some of these 
patients give a lengthy history of 
non-specific urinary problems such 
as frequency and dysuria, in others 
the history is short. In both instances 
unless the condition is controlled, 
there is a rapid progression to 
multicentric invasive high-grade 
tumours, rendering the prospect of 
cystectomy ;more proximate. These 
changes in the epithelial lining are 
often accompanied by oedema and a 
marked increase in the vascularity 
of the underlying stroma to the 
extent that the appearances of such 
bladders are also pathognomonic on 
cystoscopic examination. 
BCG THERAPY 
The treatment of carcinoma in situ 
(eIS) occurring in isolation is even 
more problematic than that of 
multiple bladder tumours. Applying 
a treatment regime formerly used 
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with other neoplasms, various 
centres in North America, and 
elsewhere (includin~ the Western 
General Hospital m Edinburgh) 
have attempted to control this 
condition by using instillations of 
commercially-available suspensions 
of BCG (Bacille Calmette-Guerin) 
into the bladders of these patients 
(9;10;11;12;13). Up to 80% 
successful control of urothelial C I S 
has been documented (14). BCG 
has also been tried, but with less 
consistent success, in widespread 
superficial bladder tumours which 
have escaped other conventional 
forms of therapy. 
In successfully treated patients, the 
end-result of such treatment is very 
satisfactory in that the 
carcinomatous urothelium sloughs 
off and the bladder seems to grow a 
new .urothelium which bears no 
resemblance to the atypical 
urothelium present prior to the 
commencement of therapy. The 
method by which such a suspension 
of Mycobacteria can achieve its 
effects is still controversial. 
The strain of BCG used at the 
Western General Hospital, 
Edinburgh is the Evans strain (15) 
which is a lyophilised preparation 
containing 1 to 5 x 10 9 colony 
forming units in 60 mg. (14). This 
quantity is suspended in 60 cc. of 
saline and instilled into the bladder 
of the patient through an intra­
urethral catheter. The patient is 
instructed to retain the suspension 
for a maximal period of two hours. 
This treatment is then repeated 
eveI)' week in succession for a total 
of eIght weeks. 
In a preliminary study on bladder 
biopsies removed from a small group 
of patients treated in this manner, 
there was an indication that after 
BCG treatment commenced, there 
were major alterations in the 
quantities and varieties of 
immunocompetent cells within such 
bladders, over and above the florid, 
organised granulomatous reaction 
which is seen in the submucosa of 
these biopsies after the first two 
weeks of therapy (16). These 'chronic 
inflammatory changes' were 
accompanied by a gradual 
denudation of the entire urothelium, 
as the further weeks of BCG 
exposure passed by (17). 
PROSPECTIVE STUDY 

A further prospective study (18) was 
therefore instituted in ten patients 
who were subjected to a similar 
treatment regime. In 9 of these 
patients there was evidence of 
carcinoma in situ with involvement 
of more than 50% of the entire 
bladder lining: in five of these 
patients, this was accompanied by 
superficial bladder tumour 
formation (T 1 or G 3 pTa). In the 
other patient there was widespread 
superficial tumour of intermediate 
malignancy (G 2 pTa). 
The ages of these patients ranged 
from 44 to 80 years, with a mean age 
of 61.4 years. Biopsies were taken 
from the bladders before the 
commencement of treatment, 
between the fourth and fifth BCG 
instillation, and at two weeks after 
that the treatment course had been 
completed. Check cystoscopies were 
also carried out at three-monthly 
intervals and material was also 
taken for histol()Eical examination 
at these times. The four quadrants 
of the bladder were biopsied 
routinely in addition to any visually 
abnormal, heaped up or 'mossy' area 
which was identifiable 
cystoscopically. The biopsies were 
taken by the 'cold cup' method and 
after portions were removed for 
ordinary fixation and histological 
assessment, other portions were 
snap- frozen in liquid nitrogen at ­
70 degrees Centigrade and stored at 
this temperature. CJyostat sections 
were then cut at 5 to 10 micron 
thickness at - 20 degrees Centigrade, 
air dried and fixed in acetone, and 
either used immediately or re-stored 
at - 20 degrees Centigrade covered 
in aluminium foil. 
Controls were obtained from the 
bladders of organ transplant ' 
beating heart' donors and from other 
cystoscopies carried out as part of 
the work-up of patients with urinary 
symptoms. Biopsy material was 
obtained and treated in a similar 
manner from patients with chronic 
non-specific cystitis, post-irradiation 
cystitis, follicular cystitis and from 
patients requiring a check­
cystoscopy eight weeks after 
Mitomycin C instillation for 
superficial bladder tumours. 
The immunohistochemical staining 
was carried out by using very specific 
commercially available, monoclonal 
antibodies directed at T lymphocytes 
and their subsets, B lvrnphocytes, 
macrophages and denaritic cells, 
and also at specific surface epitopes 
for major histocompatibility 
antigens and interleukin - 2 
receptors. The reaction was 
enhanced by using a combined 
biotin-streptavidin technique in a 
multilayer 'sandwich' technique. 
The enzymatic marker for the 
reaction was alkaline phosphatase, 
developed by a tinctorial reaction 
with Fast Red TR / Naphthol AS­
:MX phosphate substrate at pH 9.2 
in veronal buffer. The sections were 
counterstained with Mayer's 
haematoxj:'lin, and mounted in 
glycerin jelly. Optimal dilutions of 
the antibodies were identified in 
preceding experiments. Each 
section was examined independently 
and blind by two obseIVers. 
RESULTS 
These studies confirmed that the 
normal bladder wall contains very 
few T and B cells. Lymphocytic 
infiltration is also not increased 
significantly in bladders showing 
malignancy. As expected, B cells 
were more prominent in those 
bladders showing cystitis. The 
control bladders and the 
carcinomatous bladders prior to 
treatment expressed HLA - ABC 
major histocompatibility antigens 
on their swfaces but no HIA - DR 
class II histocompatibility epitopes 
(Table 1). 
After BCG treatment the HLA - DR 
antigens become very prominently 
expressed on the epithelial cells. No 
such changes were obseIVed after 
mitomycin C therapy. The change 
in the expression of the surface 
histocompatibility epitopes was 
accompanied by a major influx of T 
cells, with a less pronounced 
infiltration with B lymphocytes and 
macrophages. When an analysis 
was made of the subsets of the 
infiltrating T lymphocytes there 
appeared to be a reversal of the T 4 
to T 8 ratio with an increasing 
preponderance of T 8 (cytotoxic) T 
cells which also showed a marked 
increase in their interleukin - 2 
swface expression, indicating that 
they were active cells (Table, 2, 3). 
HYPOTHESIS 
On the basis of these findings and 
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other published work, it appears 
that the action of BCG is through 
the recruitment of T cells to tlie 
area. Indeed nude mice which are 
congenitally deficient in T cells and 
into whose bladders urothelial 
carcinoma cell lines had been 
explanted, will not react with BCG 
when this is inserted into their 
bladders unless they also receive a 
T cell transfusion (19). The T cells 
which infiltrate these bladders are 
memory cells resulting from 
previous sensitisation of the patient 
to the BCG or to the tubercle bacillus. 
The degree of lymphocytic and 
macrophage infiltration can indeed 
be correlated with the skin response 
to P P D (20). It is also essential that 
local contact is established between 
the organisms and the urothelium 
as has been shown when BCG was 
used formerly to treat solid tumours 
like melanoma, and the BCG has to 
be administered locally if it is to 
have any effect (21). 
The cytotoxic action on the 
malignant cells is mediated by T 
lymphocytes and the subsequent 
activity of macrophages, The T 
lymphocytes which are present are 
active cytotoxic cells as shown by 
their interleukin - 2 receptors. There 
is also evidence that gamma­
interferon and interleukin-2, which 
are produced during such activity, 
appear in the urine of these patients, 
in substantial quantities (22). 
BCG also appears to alter the surface 
components of the urothelial cells 
either directly, or through the 
activity of the locally produced 
lymphokines such as interferon, 
with some prior antigenic processing 
through the action of macrophages. 
These epithelial cella are rendered 
more inter-reactive by exposing on 
their surfaces of HLA - DR major 
histocompatibility antigens. This 
transforms them into cells with 
which T lymphocytes can react, and 
thereby a direct antitumour cell 
cytotoxic reaction is facilitated. 
'Normal' reserve cells which do not 
belong to the malignant 'clone' are 
preserved and eventually proliferate 
to cover up the sloughed off 
neoplastic urothelium. 
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RESULTS 
EXPRESSION OF HLA EPITOPES 
U ROTHE LlALCELLS HLA-ABC HLA-OR 
Normal Bladder STRONG NOTexpressed 
Chronic Cystitis STRONG Patchy 
Post-MITOMYCIN C STRONG NOTexpressed 
PRE- BCG treatment PATCHY Very PATCHY 
POST- BCG treatment STRONG Very INTENSE 
'* possibly due to fraying of urothelium 
TABLE 1 
INALTRATE WITHIN THE BLADDER SUBUMUCOSA 
TL:im!2!Jg. BL:imgbg. Ma;rooha NK~I§ Dendriti~ 
f\ORMAL BLADDER + - + -/ + + 
(1.3&HPF) 

CHRONIC CYSTITIS (VARIABLE) 

POST-MITOMYCIN C + - + +/ - + 

PRE-BCG instill. ++ + ++ +/- + 

(38.8IHPF) 

POST-BCG instill. ++++ ++ +++ +/- + 

(1391HPF) 

(at six months) +++ 

(81.3IHPF) 

.. 
TABLE 2 
III 
T L YMPHOCYTE INRLTRATE IN THE SUBMUCOSA 
Subset analysis MeanlL2 Class II 
XT4:T8 Ratio Receptor MHG-HLA-DR 
Expression 
NOR1v1AL 0.68 - ­
BLADDER 
PRE-BCG 4.96 9'/0 + 
TREATMENT 
POST-BCG 3.13 282% ++ 

TREATMENT 

TABLE 3 
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